Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes

阿柏西普 黄斑变性 糖尿病性黄斑水肿 医学 眼科 血管抑制剂 哌加他尼 贝伐单抗 脉络膜新生血管 胎盘生长因子 临床试验 血管内皮生长因子 黄斑水肿 糖尿病性视网膜病变 糖尿病 外科 内科学 血管内皮生长因子受体 视网膜 化疗 内分泌学
作者
Hansjürgen Agostini,Francis M. Abreu,Caroline R. Baumal,Dolly Shuo-Teh Chang,Karl G. Csaky,Anna Maria Demetriades,Laurent Kodjikian,Jennifer I. Lim,Philippe Margaron,Jordi Monés,Tünde Pető,Federico Ricci,Matthias Rüth,Rishi P. Singh,Ivaylo Stoilov,Balakumar Swaminathan,Jeffrey Ryuta Willis,Peter D. Westenskow
出处
期刊:Graefes Archive for Clinical and Experimental Ophthalmology [Springer Science+Business Media]
卷期号:262 (11): 3437-3451 被引量:53
标识
DOI:10.1007/s00417-024-06531-9
摘要

Intravitreal anti-vascular endothelial growth factor (VEGF) therapy is the standard of care for diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD); however, vision gains and anatomical improvements are not sustained over longer periods of treatment, suggesting other relevant targets may be needed to optimize treatments. Additionally, frequent intravitreal injections can prove a burden for patients and caregivers. Angiopoietin-2 (Ang-2) has been explored as an additional therapeutic target, due to the involvement of Ang-2 in DME and nAMD pathogenesis. Recent evidence supports the hypothesis that targeting both VEGF and Ang-2 may improve clinical outcomes in DME and nAMD compared with targeting VEGF alone by enhancing vascular stability, resulting in reduced macular leakage, prevention of neovascularization, and diminished inflammation. Faricimab, a novel bispecific antibody that targets VEGF-A and Ang-2, has been evaluated in clinical trials for DME (YOSEMITE/RHINE) and nAMD (TENAYA/LUCERNE). These trials evaluated faricimab against the anti-VEGFA/B and anti-placental growth factor fusion protein aflibercept, both administered by intravitreal injection. In addition to faricimab efficacy, safety, and pharmacokinetics, durability was evaluated during the trials using a treat-and-extend regimen. At 1 year, faricimab demonstrated non-inferior vision gains versus aflibercept across YOSEMITE/RHINE and TENAYA/LUCERNE. In YOSEMITE/RHINE, faricimab improved anatomic parameters versus aflibercept. Reduction of central subfield thickness (CST), and absence of both DME and intraretinal fluid were greater in faricimab- versus aflibercept-treated eyes. In TENAYA/LUCERNE, CST reductions were greater for faricimab than aflibercept at the end of the head-to-head phase (0-12 weeks), and were comparable with aflibercept at year 1, but with less frequent dosing. CST and vision gains were maintained during year 2 of both YOSEMITE/RHINE and TENAYA/LUCERNE. These findings suggest that dual Ang-2/VEGF-A pathway inhibition may result in greater disease control versus anti-VEGF alone, potentially addressing the unmet needs and reducing treatment burden, and improving real-world outcomes and compliance in retinal vascular diseases. Long-term extension studies (RHONE-X, AVONELLE-X) are ongoing. Current evidence suggests that dual inhibition with faricimab heralds the beginning of multitargeted treatment strategies inhibiting multiple, independent components of retinal pathology, with faricimab providing opportunities to reduce treatment burden and improve outcomes compared with anti-VEGF monotherapy.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
lys完成签到 ,获得积分10
刚刚
得之我幸完成签到,获得积分10
刚刚
随心所欲完成签到 ,获得积分10
刚刚
1秒前
雯雯完成签到 ,获得积分10
1秒前
无花果完成签到,获得积分10
1秒前
Regn完成签到 ,获得积分10
1秒前
南平完成签到 ,获得积分10
1秒前
selinann完成签到,获得积分10
2秒前
2秒前
3秒前
薇子完成签到,获得积分10
4秒前
化工兔发布了新的文献求助10
4秒前
卿君完成签到,获得积分10
4秒前
4秒前
撇弃途上完成签到,获得积分10
5秒前
佳佳发布了新的文献求助10
5秒前
liqunzhang发布了新的文献求助10
5秒前
tyccc完成签到,获得积分10
6秒前
阿呆盘阿瓜完成签到,获得积分10
6秒前
6秒前
茂利完成签到,获得积分10
7秒前
文艺月亮完成签到,获得积分10
7秒前
Junt完成签到,获得积分10
8秒前
阮文名完成签到,获得积分10
8秒前
hy发布了新的文献求助10
8秒前
香蕉觅云的应助被wyzgood采纳,获得10
9秒前
啦啦完成签到,获得积分10
9秒前
SheepOne完成签到,获得积分10
9秒前
LSY完成签到,获得积分10
10秒前
阿飞发布了新的文献求助10
10秒前
10秒前
小黄人完成签到,获得积分10
10秒前
五五完成签到,获得积分10
11秒前
舒心易烟完成签到,获得积分10
11秒前
辛勤小蘑菇完成签到 ,获得积分10
11秒前
小斌发布了新的文献求助10
11秒前
LHP完成签到,获得积分0
11秒前
糟糕的修杰完成签到,获得积分10
11秒前
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173463
求助须知:如何正确求助?哪些是违规求助? 9565690
关于积分的说明 21781315
捐赠科研通 7767647
什么是DOI,文献DOI怎么找? 3431597
关于科研通互助平台的介绍 2555855
邀请新用户注册赠送积分活动 2476808